Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, Irvine
With
American College of Radiology Imaging Network
Massachusetts General Hospital
University of Pennsylvania
Dartmouth-Hitchcock Medical Center
University of San Francisco
M.D. Anderson Cancer Center
Boston University
Beckman Laser Institute University of California Irvine
The investigators are testing the effectiveness of an experimental imaging technology known as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment (shrinkage of tumor).
Diffuse optical spectroscopic imaging measurements are made with a laser breast scanner. This bedside-capable system combines frequency-domain photon migration with steady-state tissue spectroscopy to measure complete(broadband) near-infrared absorption and reduced scattering spectra of breast tissue in vivo. Diffuse Optical Spectroscopy Imaging measurements are made by placing the hand-held probe on the tissue surface and moving the probe to discrete locations along a grid pattern at 1.0 cm intervals. The portable high-bandwidth Frequency-Domain Photon Migration instrument employs intensity-modulated diode lasers and conventional steady-state lamps as sources and an avalanche photodiode as the detector. The time required to perform an Frequency-Domain Photon Migration measurement depends on the desired precision and number of sweeps.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female, 18 years of age or older, non pregnant or nursing.
Diagnosis of breast cancer and will be receiving chemo therapy treatments
You may not be if
18 years of age or younger, pregnant or nursing.
Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
Previous diagnosis with other form of cancer.
Clareo Health | Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
